Aflibercept
Abstract
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources